Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics (ACRS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Aclaris Therapeutis (ACRS) PT Raised to $56 at Leerink Partners
January 8, 2018 10:13 AM ESTLeerink Partners raised its price target on Aclaris Therapeutis (NASDAQ: ACRS) to $56.00 (from $54.00) while maintaining a Outperform rating.
... More